Chemomab Therapeutics (ADR) (CMMB)
Develops nebokitug, a CCL24-neutralizing antibody for fibro-inflammatory diseases.
Something off on this page? Send us feedback.
Develops nebokitug, an investigational CCL24-neutralizing antibody for primary sclerosing cholangitis, with a rheumatoid-arthritis expansion announced through Scipher Medicine. With no approved product, its single R&D segment depends on clinical execution, regulatory agreement, and partnerships.
Develops nebokitug (CM-101), an investigational humanized monoclonal antibody that neutralizes CCL24, a chemokine associated with inflammation and fibrosis. Primary sclerosing cholangitis is the central current program, with progress in the SPRING study and regulatory planning for a later-stage path. An announced transaction with Scipher Medicine would extend the candidate into rheumatoid arthritis through a precision-medicine approach, but closing and the resulting program structure were not established in the available record.
Operates from Israel through external clinical, manufacturing, laboratory, and regulatory-service providers, with historical trial activity across the United States, Europe, and Israel. Without an approved medicine or conventional product customers, the clinical-stage model relies on trial execution, regulatory alignment, financing, manufacturing, and potential strategic partners; CMMB trades in the United States as an American Depositary Share.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $6.7M · Total debt $0 · Total assets $10.2M · Shareholders' equity $8.7M
- Revenue
- $0
- Operating income
- −$2.3M
- Net income
- −$2.2M
No dividends on record.
| Institutions15 holders · as of Mar 31, 2026 | 5.71% | 351.6K ADS | |
| Insiders6 holders · as of Sep 1, 2026 | 8.49% | 522.3K ADS | |
| Strategic holders1 holder · as of Aug 13, 2026 | 6.14% | 377.8K ADS | |
| Otherremainder | 79.66% | 4.90M ADS |
6.16M ADS as of Aug 26, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (575.38M in the company's Sep 3, 2026 report, 6.16M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Otto ErikInsider | 6.25% | 385,000 | 13Gfiled Feb 10, 2026 ↗ |
Touchstone Global Investments Pty LtdStrategic | 6.14% | 377,814 | 13Gfiled Aug 13, 2026 ↗ |
Adar1 Capital Management, LLCInstitution | 1.30% | 80,000 ADS | 13Fas of Mar 31, 2026 |
George Adi MorInsiderdirector, officer: Chief Executive Officer | 1.12% | 68,809 ADS | Form 4filed Jun 1, 2026 ↗ |
Citadel Advisors LLCInstitution | 1.04% | 64,182 ADS | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 28, 2026 | Neil Harris Cohen | director | −1,000 | $2.80 |
| Aug 27, 2026 | Neil Harris Cohen | director | −1,304 | $2.85 |
| May 29, 2026 | George Adi Mor | director, officer: Chief Executive Officer | +9,804 | $2.07 |
- Pliant Therapeutics
Closest listed PSC pipeline rival in anti-fibrotic therapy.
- AbbVie
Leading RA immunology franchise in the announced expansion.
- Amgen
Entrenched TNF-inhibitor benchmark for rheumatoid arthritis.
- Pfizer
Oral JAK inhibition sets an established RA treatment alternative.
- Sanofi (ADR)
IL-6 biologic option in the future RA treatment set.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Chemomab Therapeutics (ADR) | $2.79 | +0.72% | $16.8M | — | — | — | — |
| Pliant Therapeutics | $1.17 | +5.41% | $71.8M | — | — | — | — |
| AbbVie | $261.51 | −0.08% | $462.37B | 73.7 | 17.2 | 7.2 | +10.2% |
| Amgen | $445.00 | +0.49% | $239.00B | 27.5 | 18.9 | 6.3 | +9.7% |
| Pfizer | $28.99 | −0.15% | $165.40B | 38.3 | 10.4 | 2.6 | +2.6% |
| Sanofi (ADR) | $44.52 | +0.12% | $106.78B | 78.2 | — | 1.9 | +11.2% |
| Median | 56.0 | 17.2 | 4.4 | +9.9% |